{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-001603","form_type":"8-K","ticker":"BICX","cik":"0001443863","company_name":"BioCorRx Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.643232+00:00","generated_at":"2026-05-24T23:29:26.587902+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCorRx acquires FDA-approved opioid withdrawal drug Lucemyra from USWM LLC","bullets":["Upfront purchase price of $400,000 paid via seller retention of 50% of net sales and net distributable profits until capped.","BioCorRx issued 500,000 shares of common stock and a warrant for 500,000 shares at $1.00 exercise price, 2-year term.","Lucemyra is first and only non-opioid FDA-approved medication for opioid withdrawal; BioCorRx expects meaningful sales and positive cash flow.","BioCorRx will pay a low single-digit royalty to USWM on future sales; no direct cash payment at closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-001603","json":"https://secwatch.observer/filing/0001477932-25-001603.json","markdown":"https://secwatch.observer/filing/0001477932-25-001603.md","text":"https://secwatch.observer/filing/0001477932-25-001603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/0001477932-25-001603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1443863/000147793225001603/bicx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:29:26.587902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}